Paul Kenny, PhD, Recognized for Outstanding Basic Research Contributions to Neuropsychopharmacology
Paul Kenny, PhD, the Ward-Coleman Professor and Chair of the Department of Neuroscience at the Icahn School of Medicine at Mount Sinai, has been awarded the 2018 Daniel H. Efron Research Award from the American College of Neuropsychopharmacology (ACNP). The award is given in recognition of outstanding basic research contributions to neuropsychopharmacology. Dr. Kenny was presented the award at the 57th Annual Meeting of the ACNP in Hollywood, Florida, on Monday, December 10.
In addition to his role as Chair of Neuroscience, Dr. Kenny serves as Director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai. His lab is focused on understanding the neurobiological mechanisms of drug addiction, obesity, and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors in these processes. Dr. Kenny is also involved in efforts to develop novel small-molecule therapeutic agents for the treatment of drug addiction and other psychiatric indications, and is co-founder of Eolas Therapeutics, Inc., a company committed to treating the disease of addiction.
Over the past decade, Dr. Kenny has made outstanding contributions to neuropharmacology and the molecular study of addiction. He has won numerous awards, which include Young and Distinguished Investigator Awards from the National Alliance for Research on Schizophrenia and Depression, the Jarvik-Russell Award from the Society for Research on Nicotine and Tobacco, and the Jacob P. Waletzky Memorial Award from the Society for Neuroscience. He has also received the Tom Connor Distinguished Investigator Award from Neuroscience Ireland.
“Dr. Kenny is absolutely spectacular. He has the highest of ethical standards and he has earned the respect of his colleagues and peers,” said Eric J. Nestler, MD, PhD, Dean for Academic and Scientific Affairs at the Icahn School of Medicine at Mount Sinai and Director of The Friedman Brain Institute at Mount Sinai. “I am confident that his world-class research program will continue to make ground-breaking contributions to our understanding of drug addiction, discoveries that could rapidly set the stage for the development of novel therapeutic interventions.”
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.